Fennec Pharmaceuticals Management
Management criteria checks 2/4
Fennec Pharmaceuticals' CEO is Rosty Raykov, appointed in Jul 2009, has a tenure of 15.33 years. total yearly compensation is $2.54M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $268.06K. The average tenure of the management team and the board of directors is 4.5 years and 10.6 years respectively.
Key information
Rosty Raykov
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 23.9% |
| CEO tenure | 15.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.5yrs |
| Board average tenure | 10.6yrs |
Recent management updates
Recent updates
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
Oct 04
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 01Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?
Mar 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$1m |
| Jun 30 2024 | n/a | n/a | US$3m |
| Mar 31 2024 | n/a | n/a | US$3m |
| Dec 31 2023 | US$3m | US$607k | -US$16m |
| Sep 30 2023 | n/a | n/a | -US$20m |
| Jun 30 2023 | n/a | n/a | -US$26m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$614k | US$503k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$21m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$3m | US$468k | -US$17m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$19m |
| Dec 31 2020 | US$2m | US$430k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$1m | US$489k | -US$13m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$1m | US$350k | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$450k | US$263k | -US$7m |
Compensation vs Market: Rosty's total compensation ($USD2.54M) is above average for companies of similar size in the US market ($USD651.15K).
Compensation vs Earnings: Rosty's compensation has increased whilst the company is unprofitable.
CEO
Rosty Raykov (48 yo)
15.3yrs
Tenure
US$2,540,940
Compensation
Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of c Pharmaceuticals Inc. since July 2009. Mr. Raykov is an Independent Director of Lavras Gold Corp. since April 1, 2022. Mr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$2.54m | 0.24% $ 268.1k | |
| Chief Financial Officer | 9yrs | US$1.31m | 0.41% $ 450.2k | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Chief Strategy Officer | less than a year | no data | no data | |
| Controller | 9yrs | no data | no data | |
| President of Pharstat Inc | no data | no data | no data |
4.5yrs
Average Tenure
Experienced Management: FENC's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$2.54m | 0.24% $ 268.1k | |
| Independent Director | 13.3yrs | US$173.18k | 0.18% $ 196.2k | |
| Independent Chairman of the Board | 10.6yrs | US$225.23k | 0.78% $ 862.8k | |
| Independent Director | 5.2yrs | US$153.81k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$166.31k | 0% $ 0 |
10.6yrs
Average Tenure
69yo
Average Age
Experienced Board: FENC's board of directors are seasoned and experienced ( 10.6 years average tenure).